Home . Immediapress . Chimica e Farmacia . PharmaMar Signs a Commercialization and Distribution License Agreement for Aplidin® (plitidepsin) with Megapharm in Israel

PharmaMar Signs a Commercialization and Distribution License Agreement for Aplidin® (plitidepsin) with Megapharm in Israel

CHIMICA E FARMACIA

MADRID, January 2, 2018 /PRNewswire/ --

PharmaMar (MCE:PHM) has announced today a commercialization and distribution license agreement with Megapharm Ltd. for the marine-derived anticancer drug Aplidin® (plitidepsin) in Israel and the territory known as the Palestinian Authority.

     (Logo: http://photos.prnewswire.com/prnh/20150203/727958-b )

According to the agreement Megapharm will register Aplidin® on behalf of PharmaMar and distribute the compound in both regions. PharmaMar will retain exclusive production rights and will supply the finished product for clinical and commercial use. 

Aplidin® is PharmaMar´s second most advanced anticancer drug which is currently under development for the treatment of multiple myeloma and angioimmunoblastic T-cell lymphoma. The Company announced in March 2016 that plitidepsin has shown positive results in a pivotal Phase III clinical trial (ADMYRE) for multiple myeloma[i].

According to Luis Mora, Managing Director of PharmaMar´s Oncology Business Unit, "we are about to address our first strategic alliance with Megapharm for the commercialization of Aplidin®formultiple myeloma in Israel and the territory known as the Palestinian Authority. Our commitment is to bring a novel and first-in-class therapy to patients in need."

Miron Drucker, CEO of Megapharm, stated that "the agreement between PharmaMar and Megapharm offers a major advance for healthcare in our territory as Aplidin®provides a novel mechanism of action for treating multiple myeloma; we hope to bring access to the most innovative treatments to our patients in Israeland the territory known as the Palestinian Authority".

i. https://www.pharmamar.com/2016/03/31/aplidin-shows-positive-results-in-pivotal-phase-iii-clinical-trial-for-multiple-myeloma/

 

Contact Details: Media Relations (+34-638-79-62-15) and Investor Relations (+34-914444500)

RIPRODUZIONE RISERVATA © Copyright Adnkronos.